By Fineline Cube 
South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY). The partnership aims to utilize Rznomics’ proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.
Focus on Sensorineural Hearing Loss
The collaboration will concentrate on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research in accordance with jointly approved research plans, while Lilly will take over further development and commercialization efforts. This strategic partnership highlights the potential of RNA-based therapies in addressing significant unmet medical needs.
Financial Terms
If Lilly exercises all available options under the agreement, the total deal value could exceed USD 1.3 billion. Additionally, Rznomics will be eligible to receive separate royalties on product sales. This collaboration underscores Rznomics’ innovative capabilities and positions both companies at the forefront of RNA-based therapeutic development.-Fineline Info & Tech